Repligen Acquires Bioprocessing Analytics Portfolio from 908 Devices
Repligen Acquires Bioprocessing Analytics Portfolio from 908 Devices
Repligen Corporation, a leader in bioprocessing technology, has announced the acquisition of 908 Devices Inc.’s desktop portfolio for process analytical technology (PAT) applications. This acquisition strengthens it’s bioprocessing portfolio, enabling the company to provide more comprehensive solutions to its biopharmaceutical and contract development and manufacturing organization (CDMO) customers. 908 Devices, meanwhile, will shift its focus to advancing its handheld devices for health and safety applications.
Strengthening Repligen’s Bioprocessing Portfolio
The purchase from 908 Devices includes four advanced desktop devices designed to support real-time monitoring and analysis in bioprocessing workflows. These products, which are used in various stages of biomanufacturing, will complement it’s existing PAT portfolio and enhance its ability to help customers optimize development processes and improve manufacturing efficiencies.
The acquired products include:
- MAVERICK: A device designed for real-time monitoring and control of critical bioprocess parameters.
- MAVEN: A tool for controlling and analyzing bioprocess parameters in real time.
- REBEL: An at-line cell culture media analyzer that helps optimize media formulations in bioprocesses.
- ZipChip: A high-resolution sample separations device used to characterize product quality attributes.
By incorporating these devices into its portfolio, it is well-positioned to offer a more complete set of analytical solutions across the entire bioprocess workflow, from development to manufacturing.
Expanding Repligen’s Capabilities in Upstream Bioprocessing
Olivier Loeillot, President and CEO expressed excitement about the acquisition, highlighting how the addition of 908 Devices’ desktop assets will enhance the company’s capabilities in upstream bioprocessing. He said, “We are really excited to onboard the 908 bioprocessing team and the four differentiated upstream PAT technologies that are commercialized today. They are the perfect complement to our downstream analytics portfolio and will enable to further penetrate a broad set of modalities and offer analytics solutions across the entire bioprocess workflow.”
Loeillot emphasized that the acquisition would enable to better support its customers who are increasingly integrating digitization technologies into their production processes. This acquisition is seen as a strategic step in it’s ongoing efforts to expand its market presence and deliver value through innovative bioprocessing solutions.
908 Devices Focuses on Handheld Analytical Devices
While Repligen is integrating the desktop devices into its broader bioprocessing portfolio, 908 Devices will continue to focus on its handheld devices, which have gained recognition for their role in health and safety applications. The company’s handheld devices are used for chemical analysis at the point of need, providing rapid and reliable insights in various fields, including environmental monitoring and public safety.
Kevin J. Knopp, CEO and Co-founder of 908 Devices, commented on the shift in focus: “Repligen’s leadership in commercializing innovative solutions that advance bioprocessing is a great fit for our novel desktop devices and our bioprocessing team. I wish them continued success.” He went on to explain that 908 Devices would continue to innovate in chemical detection technology, particularly for critical health and safety applications.
Transaction Details and Advisors
The financial terms of the transaction include a cash payment of $70 million from Repligen to 908 Devices. The transaction is supported by key advisory teams: Centerview Partners LLC is serving as financial advisor to Repligen, while Goodwin Procter is providing legal counsel. For 908 Devices, Perella Weinberg Partners is acting as financial advisor, with Paul Hastings LLP providing legal support.
This strategic acquisition is designed to accelerate Repligen’s capabilities in process analytical technology and further strengthen its position as a leader in bioprocessing innovation.
Repligen Acquires Bioprocessing Analytics Portfolio from 908 Devices
908 Devices to Discuss Acquisition on Q4 2024 Earnings Call
908 Devices will address the divestiture of its desktop assets during a conference call scheduled for Tuesday, March 4, 2025, before market open. The call, which will cover the company’s fourth-quarter 2024 financial results, will begin at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Interested parties can access the webcast through 908 Devices’ Investor Relations website.
Conclusion: A Strategic Move for Both Companies
The acquisition of 908 Devices’ desktop bioprocessing portfolio by Repligen marks a significant milestone for both companies. Repligen’s expanded capabilities will provide its customers with a more integrated set of solutions for process optimization, while 908 Devices will continue to focus on its growing handheld portfolio for vital health and safety applications. This deal not only strengthens Repligen’s position in the bioprocessing industry but also highlights the strategic shift in focus for 908 Devices as it pursues new opportunities in chemical analysis for critical real-time applications.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in forensics, bioprocessing, pharma/biopharma, life science research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning. To learn more, visit 908devices.com.
